Algernon Pharmaceuticals Inc. (CSE: AGN)
Canada
· Delayed Price · Currency is CAD 0.0800
+0.0050 (6.67%)
Nov 22, 2024, 4:00 PM EST
Algernon Pharmaceuticals Revenue
Revenue
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
n/a
Market Cap
2.18M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Thumb Industries Inc. | 1.51B |
| Trulieve Cannabis Corp. | 1.58B |
| Cresco Labs Inc. | 981.27M |
| Grown Rogue International Inc. | 28.83M |
| Planet 13 Holdings Inc. | 147.38M |
| Ayr Wellness Inc. | 627.53M |
| Jushi Holdings Inc. | 350.48M |
| MariMed Inc. | 213.26M |
Algernon Pharmaceuticals News
- 18 days ago - Algernon Announces Warrant Extension - GlobeNewsWire
- 3 months ago - Algernon Pharmaceuticals Announces Closing of Private Placement - GlobeNewsWire
- 3 months ago - Algernon Pharmaceuticals Announces Increase to Private Placement - GlobeNewsWire
- 3 months ago - Algernon Pharmaceuticals Announces Private Placement - GlobeNewsWire
- 6 months ago - Algernon Pharmaceuticals Engages ICP Securities Inc. for Automated Market Making Services - GlobeNewsWire
- 7 months ago - Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024 - GlobeNewsWire
- 8 months ago - Algernon Pharmaceuticals CEO Christopher J. Moreau to Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar on April 16th, 2024 - GlobeNewsWire
- 8 months ago - Algernon Pharmaceuticals to Move Forward with Psychedelic Drug DMT Stroke Research Program as its Lead Asset - GlobeNewsWire